Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration - PubMed (original) (raw)
. 2009 Mar 15;115(6):1224-33.
doi: 10.1002/cncr.24135.
Collaborators, Affiliations
- PMID: 19156917
- DOI: 10.1002/cncr.24135
Free article
Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration
Vitaly Margulis et al. Cancer. 2009.
Free article
Abstract
Background: The literature on upper tract urothelial carcinoma (UTUC) has been limited to small, single center studies. A large series of patients treated with radical nephroureterectomy for UTUC were studied, and variables associated with poor prognosis were identified.
Methods: Data on 1363 patients treated with radical nephroureterectomy at 12 academic centers were collected. All pathologic slides were re-reviewed by genitourinary pathologists according to strict criteria.
Results: Pathologic review revealed renal pelvis location (64%), necrosis (21.6%), lymphovascular invasion (LVI) (24.8%), concomitant carcinoma in situ (28.7%), and high-grade disease (63.7%). A total of 590 patients (43.3%) underwent concurrent, lymphadenectomy and 135 (9.9%) were lymph node (LN) -positive. Over a mean follow-up of 51 months, 379 (28%) patients experienced disease recurrence outside of the bladder and 313 (23%) died of UTUC. The 5-year recurrence-free and cancer-specific survival probabilities (+/-SD) were 69%+/-1% and 73%+/-1%, respectively. On multivariate analysis, high tumor grade (hazards ratio [HR]: 2.0, P<.001), advancing pathologic T stage (P-for-trend<.001), LN metastases (HR: 1.8, P<.001), infiltrative growth pattern (HR: 1.5, P<.001), and LVI (HR: 1.2, P=.041) were associated with disease recurrence. Similarly, patient age (HR: 1.1, P=.001), high tumor grade (HR: 1.7, P=.001), increasing pathologic T stage (P-for-trend<.001), LN metastases (HR: 1.7, P<.001), sessile architecture (HR: 1.5, P=.002), and LVI (HR: 1.4, P=.02) were independently associated with cancer-specific survival.
Conclusions: Radical nephroureterectomy provided durable local control and cancer-specific survival in patients with localized UTUC. Pathologic tumor grade, T stage, LN status, tumor architecture, and LVI were important prognostic variables associated with oncologic outcomes, which could potentially be used to select patients for adjuvant systemic therapy.
Copyright (c) 2009 American Cancer Society.
Similar articles
- Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M, Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H, Martínez-Salamanca JI, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz PI, Margulis V. Cha EK, et al. Eur Urol. 2012 Apr;61(4):818-25. doi: 10.1016/j.eururo.2012.01.021. Epub 2012 Jan 23. Eur Urol. 2012. PMID: 22284969 - Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study.
Fernández MI, Shariat SF, Margulis V, Bolenz C, Montorsi F, Suardi N, Remzi M, Wood CG, Roscigno M, Kikuchi E, Oya M, Zigeuner R, Langner C, Weizer A, Lotan Y, Koppie TM, Raman JD, Karakiewicz P, Bensalah K, Schultz M, Bernier P. Fernández MI, et al. Urology. 2009 Jan;73(1):142-6. doi: 10.1016/j.urology.2008.07.042. Epub 2008 Oct 8. Urology. 2009. PMID: 18845322 - Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer.
Roscigno M, Brausi M, Heidenreich A, Lotan Y, Margulis V, Shariat SF, Van Poppel H, Zigeuner R. Roscigno M, et al. Eur Urol. 2011 Oct;60(4):776-83. doi: 10.1016/j.eururo.2011.07.009. Epub 2011 Jul 14. Eur Urol. 2011. PMID: 21798659 Review. - The prognostic role of lymphovascular invasion in urothelial-cell carcinoma of upper and lower urinary tract.
Brunocilla E, Pernetti R, Martorana G. Brunocilla E, et al. Anticancer Res. 2011 Oct;31(10):3503-6. Anticancer Res. 2011. PMID: 21965769 Review.
Cited by
- Predictors of recurrence and patterns of failure among patients treated with nephroureterectomy for upper tract urothelial carcinoma.
Hughes RT, Lucas JT, Krane LS, Divers JL, Hemal AK, Frizzell BA. Hughes RT, et al. Cancer Treat Commun. 2016;5:39-45. doi: 10.1016/j.ctrc.2015.12.004. Epub 2015 Dec 21. Cancer Treat Commun. 2016. PMID: 39363914 Free PMC article. - Disitamab vedotin (RC48) long-term regimen in a post-nephroureterectomy patient with metastases: a case report.
Li W, Jing S, Zhao B, Jiang W, Zhang B. Li W, et al. Front Oncol. 2024 Sep 13;14:1419882. doi: 10.3389/fonc.2024.1419882. eCollection 2024. Front Oncol. 2024. PMID: 39346730 Free PMC article. - Radiomics-Based Computed Tomography Urogram Approach for the Prediction of Survival and Recurrence in Upper Urinary Tract Urothelial Carcinoma.
Alqahtani A, Bhattacharjee S, Almopti A, Li C, Nabi G. Alqahtani A, et al. Cancers (Basel). 2024 Sep 10;16(18):3119. doi: 10.3390/cancers16183119. Cancers (Basel). 2024. PMID: 39335090 Free PMC article. - Urothelial cancer: state of art in Ukraine and improvement pathways.
Pikul M, Gordiichuk P, Stakhovsky E. Pikul M, et al. Ann Med Surg (Lond). 2024 Aug 6;86(9):5137-5144. doi: 10.1097/MS9.0000000000002424. eCollection 2024 Sep. Ann Med Surg (Lond). 2024. PMID: 39238972 Free PMC article. - [The metastatic and advanced upper tract urothelial carcinoma-a separate entity or bladder cancer's younger sibling?].
Haas M, Bahlinger V, Burger M, Bolenz C, Ma Y. Haas M, et al. Urologie. 2024 Oct;63(10):1011-1018. doi: 10.1007/s00120-024-02421-4. Epub 2024 Sep 2. Urologie. 2024. PMID: 39223346 Review. German.
MeSH terms
LinkOut - more resources
Full Text Sources